The abstract is read at the publisher; the summary is JClub's.
Trametinib induces a robust senescent phenotype in BT-40 paediatric BRAF-V600E glioma tumours in vivo, and Navitoclax senolysis linked to BCL-xL inhibition ablates those cells.
- Why it matters: Standard low-dose chemotherapy and MAPK inhibition often show initial responses in children with BRAF-V600E brain tumours, but relapse after treatment withdrawal limits durable control.
- What they did: In vitro and after orthotopic transplantation into mice, paediatric low-grade glioma models were treated with Dabrafenib, Trametinib, Tovorafenib, or Vinblastine; senescence was measured by molecular and cytological markers, then senolytic sensitivity was tested with dose-response assays and in vivo combinations.
- The result: Navitoclax was identified as a potent senolytic against senescent BT-40 cells, and combined Trametinib plus Navitoclax ablated senescent tumour cells, reduced tumour regrowth after withdrawal, and improved survival.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.